Alirocumab: A Review in Hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Hypercholesterolemia poses significant cardiovascular risk.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of LDL cholesterol metabolism.
• Novel therapeutic strategies are needed for patients with inadequately controlled LDL-C levels.

Purpose of the Study:

• To evaluate the efficacy and tolerability of alirocumab in patients with hypercholesterolemia.
• To assess alirocumab's effect on low-density lipoprotein-cholesterol (LDL-C) reduction compared to other lipid-lowering therapies.
• To investigate alirocumab's long-term efficacy and impact on other lipid parameters.

Main Methods:

• Ten Phase III studies (ODYSSEY program) involving patients with heterozygous familial hypercholesterolemia (heFH) or nonfamilial hypercholesterolemia (nonFH).
• Subcutaneous administration of alirocumab (75 or 150 mg every 2 weeks) as monotherapy or in combination with other lipid-lowering therapies.
• Comparison against matching placebo, ezetimibe, or modified oral statin therapy over 24 weeks, with longer-term follow-up (52-78 weeks).

Main Results:

• Alirocumab significantly reduced LDL-C levels compared to comparator agents over 24 weeks.
• Sustained LDL-C lowering efficacy was observed over 52-78 weeks.
• Alirocumab demonstrated favorable effects on non-high-density lipoprotein-cholesterol (non-HDL-C) and lipoprotein (a) [Lp(a)] and was generally well tolerated.

Conclusions:

• Alirocumab is an effective treatment for reducing LDL-C in patients with hypercholesterolemia, including those with statin intolerance.
• The drug offers sustained lipid-lowering benefits and a favorable safety profile.
• Further research is warranted to confirm the cardiovascular benefits of alirocumab.